Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pimavanserin tartrate (Nuplazid) is an effective and specific serotonin 5-HT2A inverse agonist (pIC50: 8.73), used in the therapy of psychosis associated with Parkinson's disease.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
25 mg | 在庫あり | ¥ 10,000 | |||
50 mg | 在庫あり | ¥ 16,000 | |||
100 mg | 在庫あり | ¥ 26,000 | |||
200 mg | 在庫あり | ¥ 33,500 | |||
500 mg | 在庫あり | ¥ 55,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 11,000 |
説明 | Pimavanserin tartrate (Nuplazid) is an effective and specific serotonin 5-HT2A inverse agonist (pIC50: 8.73), used in the therapy of psychosis associated with Parkinson's disease. |
ターゲット&IC50 | 5-HT2A:8.7(pIC50) |
In vivo | In rats, Pimavanserin (3 mg/kg, p.o.) attenuates DOI-induced head twitches. In mice, Pimavanserin (3 mg/kg, p.o.) significantly attenuates MK-801-induced hyperactivity. [1] In a rat model of parkinsonian tremor, Pimavanserin (40 mg/kg, i.p.) produces a significant overall reduction of tacrine-induced tremulous jaw movements. [2] |
別名 | ACP-103, ACP-103 tartrate, Nuplazid, Pimavanserin |
分子量 | 1005.2 |
分子式 | C50H68F2N6O4·C4H6O6 |
CAS No. | 706782-28-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 93 mg/mL (92.5 mM)
DMSO: 60 mg/mL (59.69 mM)
H2O: 92 mg/mL (91.5 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pimavanserin tartrate 706782-28-7 GPCR/G Protein Neuroscience 5-HT Receptor Inhibitor Pimavanserin hemitartrate 5-hydroxytryptamine Receptor ACP-103 ACP-103 tartrate ACP-103 Tartrate ACP-103 hemitartrate ACP 103 Tartrate Nuplazid inhibit Pimavanserin ACP103 Tartrate ACP 103 Serotonin Receptor ACP103 Pimavanserin Tartrate inhibitor